Bilbao, Idoia
Recalde, Miriam
Daian, Fabrice
Herranz, José Maria
Elizalde, María
Iñarrairaegui, Mercedes
Canale, Matteo
Fernández-Barrena, Maite G.
Casadei-Gardini, Andrea
Sangro, Bruno
Ávila, Matías A.
Landecho Acha, Manuel F.
Berasain, Carmen
Arechederra, María
Funding for this research was provided by:
Ministerio de Ciencia e Innovación (BES-2017-079883, RYC2018-024475-1)
Instituto de Salud Carlos III (SCIII) cofinanced by ‘Fondo Europeo de Desarrollo Regional’ (FEDER) ‘Una Manera de Hacer Europa’ (PI19/00613)
Fundación Científica Asociación Española Contra el Cáncer (INVES223049AREC)
Universidad de Navarra
Article History
Received: 26 June 2024
Accepted: 27 August 2024
First Online: 21 September 2024
Declarations
:
: Not applicable.
: BS reports consultancy fees from Adaptimmune, Astra Zeneca, Bayer, BMS, Boston Scientific, Eisai, Eli Lilly, Incyte, Ipsen, Novartis, MSD, Roche, Sanofi, Sirtex Medical, Terumo; speaker fees from Astra Zeneca, Bayer, BMS, Eisai, Eli Lilly, Incyte, Ipsen, Novartis, Roche, Sirtex Medical, Terumo; research grants (to the Institution) from BMS and Sirtex Medical. Rest of the authors have nothing to declare.